Delaware is currently home to 302 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Newark, Wilmington, Lewes and Rehoboth Beach. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Christiana Hospital, Newark, Delaware
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
NCT05323734
Recruiting
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy. The study consists of a 4-week prospective Baseline phase, defined as the first 28 days following screening, followed by a double-blind phase consisting of a 4-week titration period (Day 1 to Day 28) and a 12-week maintenance period (Day 29 to Week 16).
Gender:
All
Ages:
Between 1 year and 65 years
Trial Updated:
10/18/2023
Locations: Nemours Children's Hospital - Delaware Valley, Wilmington, Delaware
Conditions: Tuberous Sclerosis Complex
Register for Updates
EASE: The Materna Prep Pivotal Study
NCT03973281
Recruiting
This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device d... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Christiana Care - Center for Women's & Children's Health, Newark, Delaware
Conditions: Vaginal Delivery, Pelvic Organ Prolapse
Register for Updates
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
NCT03793478
Recruiting
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
Gender:
All
Ages:
Between 1 month and 21 years
Trial Updated:
10/11/2023
Locations: A.I. duPont Hospital for Children, Wilmington, Delaware
Conditions: Acute Myeloid Leukemia
Register for Updates
The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
NCT05067998
Recruiting
Herbal Medicine is known as the medicinal use of herbal substances as a means of treating different conditions in the human body to ensure that the body remains in optimal health and wellness. These substances are known to contain very active ingredients in it and as such is also a very potent means of managing diseases and ailments in the body. Herbal medicine has always been a standby source of getting relief from various conditions over centuries, however, it can be categorically said that t... Read More
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
10/06/2023
Locations: Health for Life Holistic Wellness Center LLC, Dover, Delaware
Conditions: Anxiety Disorders and Symptoms, Fibromyalgia, Arthritis, Chronic Pain, Hypertension,Essential
Register for Updates
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
NCT03597581
Recruiting
RGX-202-01 (ompenaclid) is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI +/- bevacizumab. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202-01 with or without FOLFIRI +/- bevacizumab (single agent or combination therapy) will be evaluate... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Medical Oncology Hematology Consultants, PA, Newark, Delaware
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Register for Updates
Informational Meetings for Planning and Coordinating Treatment
NCT04330833
Recruiting
This prospective cluster-randomized trial examines the efficacy of a novel communication intervention delivered by trained physician and nurse dyads to parents of children with cancer within the clinicians' practice, to foster alignment of the goals of treatment. The investigators hypothesize that goal alignment will improve quality of life outcomes, in particular for those patients who reach end of life. Findings from the proposed research will provide essential information to promote communica... Read More
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
10/01/2023
Locations: Nemours Children's Health, Wilmington, Delaware
Conditions: End of Life, Communication, Cancer Metastatic
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
09/29/2023
Locations: Novartis Investigative Site, Newark, Delaware
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05271604
Recruiting
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 in PD-1/L1 failure patients with ROR-2 expression in recurrent or metastatic squamous cell carcinoma of the head and neck.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Christiana Care Helen Graham Cancer Center, Newark, Delaware
Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Primordial Dwarfism Registry
NCT04569149
Recruiting
The goal of this registry is to collect information on individuals with Microcephalic Osteodysplastic Primordial Dwarfism Type II (also called MOPDII) and other forms of microcephalic primordial dwarfism. The study team hopes to learn more about these conditions and improve the care of people with it by establishing this registry.
Gender:
All
Ages:
All
Trial Updated:
09/27/2023
Locations: Nemours, Wilmington, Delaware
Conditions: MOPDII, Meier-Gorlin Syndrome, Saul-Wilson Syndrome, Ligase 4 Syndrome, Microcephalic Primordial Dwarfism, RNU4atac-opathy (e.g. MOPDI/III, Lowry-Wood Syndrome, Roifman Syndrome)
Register for Updates
Rhizomelic Chondrodysplasia Punctata Registry
NCT04569162
Recruiting
The goal of this registry is to collect medical information on individuals with rhizomelic chondrodysplasia punctata and closely related conditions. The study team hopes to learn more about these conditions and improve the care of people with it by establishing this registry.
Gender:
All
Ages:
All
Trial Updated:
09/27/2023
Locations: Nemours, Wilmington, Delaware
Conditions: RCDP - Rhizomelic Chondrodysplasia Punctata, RCDP1, RCDP2, RCDP3, RCDP4, RCDP5
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
All
Ages:
Between 0 years and 2 years
Trial Updated:
09/15/2023
Locations: Nemours Alfred I. duPont Hospital for Children, Wilmington, Delaware
Conditions: SCID
Register for Updates